{{Rsnum
|rsid=2191349
|Gene=LOC100128217
|Chromosome=7
|position=15024684
|Orientation=plus
|GMAF=0.4504
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 26.2 | 52.3 | 21.5
| HCB | 6.7 | 44.4 | 48.9
| JPT | 9.1 | 36.4 | 54.5
| YRI | 23.0 | 37.7 | 39.3
| ASW | 0.0 | 0.0 | 0.0
| CHB | 6.7 | 44.4 | 48.9
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=20081858
|Trait=Fasting glucose-related traits
|Title=New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
|RiskAllele=T
|Pval=3E-17
|OR=None
|ORtxt=None
|OA=1
}}

{{PharmGKB
|RSID=rs2191349
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:20081858
|Annotation=Phenotype 1: In a meta-analysis of 21 GWAS cohorts followed by analysis in additional individuals, this SNP was found to be associated with fasting glucose level. Study size: 122,743. Significance metric(s): p = 3.0 x 10(-44). Phenotype 2: In the same study, this SNP was found to be associated with HOMA-B (homeostasis model assessment of beta-cell function). Study size: 98,372. Significance metric(s): p = 2.8 x 10(-17). Study population/ethnicity: Non-diabetic Individuals of European descent. Type of association: CO;GN.
|Drugs=
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA165281936
}}

{{omim
|id=613462
|rsnum=2191349
}}

{{PMID Auto
|PMID=21887289
|Title=Glucose-Raising Genetic Variants in MADD and ADCY5 Impair Conversion of Proinsulin to Insulin
|OA=1
}}

{{PMID|20043853|OA=1
}} Prioritizing genes for follow-up from genome wide association studies using information on gene expression in tissues relevant for type 2 diabetes mellitus.

{{PMID|20870969|OA=1
}} Genetic predisposition to long-term nondiabetic deteriorations in glucose homeostasis: Ten-year follow-up of the GLACIER study.

{{PMID|21278902|OA=1
}} Genetic risk profiling for prediction of type 2 diabetes.

{{PMID Auto GWAS
|PMID=22581228
|Trait=None
|Title=A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.
|RiskAllele=
|Pval=3E-21
|OR=None
|ORtxt=None
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2191349
|overall_frequency_n=76
|overall_frequency_d=128
|overall_frequency=0.59375
|n_genomes=46
|n_genomes_annotated=0
|n_haplomes=65
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=22698489
|Title=Nonfasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study.
}}

{{PMID Auto
|PMID=23462794
|Title=Identification of CpG-SNPs associated with type 2 diabetes and differential DNA methylation in human pancreatic islets.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}